Skip to main content

Dr. Isaac A. Bowman, MD

Medical Oncology (Medical Oncology Physician)

2946 E Banner Gateway Dr
Gilbert, AZ 85234

Who else practices at this address →

Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas

Call (480) 256-6444

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
309

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Medical school: University of Texas Southwestern Medical School at Dallas
  • 2010Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    AZ license 62482

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
309
Services billed
857
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes432154
Established patient office or other outpatient visit, 30-39 minutes262160
New patient office or other outpatient visit, 60-74 minutes6969
Telephone medical discussion with physician, 21-30 minutes5340
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes3729
Telephone medical discussion with physician, 11-20 minutes2217

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Orgovyx (relugolix)176
Prednisone
Other prescribers in Gilbert, AZ
122
Abiraterone Acetate111
Gabapentin
Other prescribers in Gilbert, AZ
62
Tamsulosin Hcl
Other prescribers in Gilbert, AZ
55
Dexamethasone
Other prescribers in Gilbert, AZ
52
Nubeqa (darolutamide)44
Xtandi (enzalutamide)43
Prochlorperazine Maleate
Other prescribers in Gilbert, AZ
43
Cabometyx (cabozantinib s-malate)43

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 10 payments worth $5,759 in total to this clinician.

By company
Pfizer Inc.$5,413
Janssen Biotech, Inc.$125
AstraZeneca Pharmaceuticals LP$85.00
Caris Mpi, Inc.$53.85
Aveo Pharmaceuticals, Inc.$41.76
Novartis Pharmaceuticals Corporation$26.00
Ferring Pharmaceuticals Inc.$14.95
By type
Consulting Fee$5,280
Food and Beverage$394
Education$85.00

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 29, 2025Pfizer Inc.
Jan 29, 2025
Consulting Fee
PADCEV · ONCOLOGY
$2,880
Jun 17, 2025Pfizer Inc.
Jun 17, 2025
Consulting Fee
TALZENNA · ONCOLOGY
$2,400
Jun 12, 2025AstraZeneca Pharmaceuticals LP
Jun 12, 2025
Education
LYNPARZA · Oncology · in-kind
Company’s descriptionEducational Item
$85.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Arizona →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $218,283 in research payments for these studies, mostly to the institutions running them.

  • A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
    AstraZeneca Pharmaceuticals LP
  • A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants…
    E.r. Squibb & Sons, L.l.c.
  • A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants…
    Celgene Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Gilbert

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 6, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1891012852. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.